Barclays
CHRS icon

Barclays’s Coherus Oncology CHRS Stock Holding History

Barclays’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,900
Closed -$119K – 4920
2024
Q1 		$119K Buy
+49,900
New +$123K ﹤0.01% 4369
2020
Q1 		– Sell
-100
Closed -$2K – 6162
2019
Q4 		$2K Buy
+100
New +$1.84K ﹤0.01% 6236
2019
Q2 		– Sell
-5,300
Closed -$72K – 6960
2019
Q1 		$72K Buy
5,300
+300
+6% +$4K ﹤0.01% 5615
2018
Q4 		$45K Buy
+5,000
New +$57.9K ﹤0.01% 5525
2018
Q2 		– Sell
-100
Closed -$1K – 6992
2018
Q1 		$1K Sell
100
-300
-75% -$3.28K ﹤0.01% 6946
2017
Q4 		$4K Buy
+400
New +$4.28K ﹤0.01% 6686

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return